Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds DA Davidson Maintains Buy on Amazon.com, Raises Price Target to $134

DA Davidson Maintains Buy on Amazon.com, Raises Price Target to $134

DA Davidson analyst Tom Forte maintains Amazon.com (NASDAQ:AMZN) with a Buy and raises the price target from $114 to $134.

byBenzinga Newsdesk

February 3, 2023

1 minute read

DA Davidson analyst Tom Forte maintains Amazon.com (NASDAQ:AMZN) with a Buy and raises the price target from $114 to $134.

Zepp Health Q1 And Outlook Lags Consensus As The Pandemic Interrupts Product Launches; Updates On AI Products

By Anusuya Lahiri

May 23, 10:10 AM

Zepp Health Corp (NYSE:ZEPP) reported a first-quarter FY23 revenue of $93.95 million, missing the consensus of $122.93 million. The 14.8%…

ZEPP

News

Aramco And Stellantis Collaboration Indicates eFuel Compatibility With European Engine Families

By Happy Mohamed

September 5, 9:14 AM

Aramco and Stellantis Collaboration Indicates eFuel Compatibility with European Engine Families Stellantis and Aramco find that 24 engine families in European vehicles produced

STLA

Analyst Ratings

In-Depth Examination Of 14 Analyst Recommendations For AvalonBay Communities

By Benzinga Insights

June 17, 1:00 PM

During the last three months, 14 analysts shared their evaluations of AvalonBay Communities (NYSE:AVB), revealing diverse outlooks from…

AVB

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies

By Vandana Singh

November 29, 9:30 AM

Tuesday, the FDA said it received reports of patients developing T-cell malig

BMY

DA Davidson Maintains Buy on Amazon.com, Raises Price Target to $134

Related Posts

Zepp Health Q1 And Outlook Lags Consensus As The Pandemic Interrupts Product Launches; Updates On AI Products

Aramco And Stellantis Collaboration Indicates eFuel Compatibility With European Engine Families

In-Depth Examination Of 14 Analyst Recommendations For AvalonBay Communities

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies